Table 1.
Characteristics of studies related to nomogram development for prostate cancer diagnosis, including multi-parametric MRI
| Study | Diagnostic work-up | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient recruitment | Diagnostic protocol | Outcome measurement | ||||||||||
| Patient groups | Year | Number of centers | Inclusion period | Criteria | Number of men | mpMRI/bpMRI | Positive | Targeted biopsy | Systematic biopsy | All PCa | csPCa | Definition csPCa |
| Biopsy-naive setting | ||||||||||||
| Alberts et al. [20] | 2018 | 5 | 2012–2017 | +PSA ± DRE | 504 | mpMRI | P3-5 | Fusion | 12-cores TR | y | y | GS ≥ 3 + 4 |
| Bjurlin et al. [24] (Urology) | 2018 | 1 | Jun 2012–Aug 2014 | +PSA ± DRE | 201 | mpMRI | P3-5 | Fusion | 12-cores TR | y | y | GS ≥ 7 |
| 1 | Jun 2012–Aug 2014 | 87 | ||||||||||
| Fang et al. [23] | 2016 | 1 | Jan 2011–Nov 2013 | +PSA ± DRE ± TRUS | 894 | mpMRI | n.r. | Cognitive | 12-cores TR | y | y | GS ≥ 4 + 3 |
| Mehralivand et al. [22] | 2018 | 1 | May 2015- Aug 2016 | +PSA ± DRE | 400 | mpMRI | P3-5 | Fusion | 12-cores TR | n | y | GS ≥ 3 + 4 |
| 2 | Apr 2013–Oct 2016 | 251 | ||||||||||
| Niu et al. [25] | 2017 | 1 | Jan 2014–Sep 2015 | +PSA ± DRE ± RUS | 151 | mpMRI | n.r. | n.r. | 12-cores TR | n | y | GS ≥ 7 |
| 1 | Oct 2015–Oct 2016 | 74 | n | y | GS ≥ 7 | |||||||
| Radtke et al. [21] | 2017 | 1 | 2012–2015 | +PSA ± DRE | 660 | mpMRI | P2-5 | fusion | 24-cores TP | n | y | GS ≥ 3 + 4 |
| Prior negative biopsy setting | ||||||||||||
| Alberts et al. [20] | 2018 | 5 | 2012–2015 | +PSA ± DRE, persistant suspicion | 504 | mpMRI | P3-5 | Fusion | 12-cores TR | y | y | GS ≥ 3 + 4 |
| Bjurlin et al. [30] (Eur Urol Focus) | 2018 | 1 | Apr 2012–Sept 2017 | +PSA ± DRE, persistant suspicion | 104 | mpMRI | P3-5 | Fusion | 12-cores TR | y | n | |
| Bjurlin et al. [24] (Urology) | 2018 | 1 | Jun 2012–Aug 2014 | +PSA ± DRE, persistant suspicion | 119 | mpMRI | P3-5 | Fusion | 12-cores TR | y | y | GS ≥ 7 |
| 1 | Jun 2012–Aug 2014 | 52 | ||||||||||
| Huang et al. [27] | 2018 | 1 | Jan 2007–Apr 2017 | +PSA ± DRE, persistant suspicion | 231 | mpMRI | P3-5 | n.r. | 12-cores TR | y | y | GS ≥3+4 |
| Radtke et al. [21] | 2017 | 1 | 2012–2017 | +PSA ± DRE, persistant suspicion | 355 | mpMRI | P2-5 | fusion | 24-cores TP | n | y | GS ≥ 3 + 4 |
| Truong [26] | 2018 | 2 | Dec 2014–Dec 2016; Feb 2014–Feb 2017 | +PSA ± DRE, persistant suspicion | 285 | mpMRI | P3-5 | Fusion | 12-cores TR | y | n | n.a. |
| Combined biopsy-naive and prior negative biopsy setting | ||||||||||||
| Lee et al. [28] | 2017 | 1 | Jul 2012–Nov 2015 | +PSA ± DRE, persistant suspicion | 615 | bpMRI | P3-5 | Fusion | 24-40 cores TP | y | y | GS ≥ 3 + 4 /MCCL ≥ 6mm |
| Van Leeuwen et al. [29] | 2018 | 1 | Apr 2012–Mar 2014 | +PSA ± DRE, persistant suspicion | 393 | mpMRI | P3-5 | Fusion/cognitive | 30-cores TP | n | y | GS ≥ 3 + 4 (> 5%)/MCCL ≥ 7 mm/ ≥ 20% core+ |
| 1 | Jan 2013–Dec 2014 | 198 | mpMRI | P3-5 | Cognitive | 18-cores TR/TP | ||||||